Previous close | 3.0500 |
Open | 3.4400 |
Bid | 0.1000 |
Ask | 0.8000 |
Strike | 200.00 |
Expiry date | 2024-05-03 |
Day's range | 0.3500 - 3.4400 |
Contract range | N/A |
Volume | |
Open interest | 71 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.